RO4938581, a novel cognitive enhancer acting at GABAA α5 subunit-containing receptors
- 1.1k Downloads
GABAA α5 subunit-containing receptors are primarily expressed in the hippocampus and their role in learning and memory has been demonstrated recently by both genetic and pharmacological approaches.
The objective of the study is to evaluate the cognitive effects of a novel GABAA α5 receptor inverse agonist, RO4938581 in rats and monkeys.
Materials and methods
The in vitro profile was determined using radioligand binding and electrophysiological assays for the GABAA α1, α2, α3, and α5 receptors. Long-term potentiation (LTP) was performed in mouse hippocampal slices. Cognitive effects were assessed in rats in the delayed match to position (DMTP) task and the Morris water maze. In monkeys, the object retrieval task was used. Pro-convulsant and anxiogenic potentials were evaluated in mice and rats. In vivo receptor occupancy was determined using [3H]-RO0154513.
RO4938581 is a potent inverse agonist at the GABAA α5 receptor, with both binding and functional selectivity, enhancing hippocampal LTP. RO4938581 reversed scopolamine-induced working memory impairment in the DMTP task (0.3–1 mg/kg p.o.) and diazepam-induced spatial learning impairment (1–10 mg/kg p.o.). RO4938581 improved executive function in monkeys (3-10 mg/kg p.o.). Importantly, RO4938581 showed no anxiogenic and pro-convulsive potential. RO4938581 dose-dependently bound to GABAA α5 receptors and approximately 30% receptor occupancy was sufficient to produce enhanced cognition in the rat.
The data further support the potential of GABAA α5 receptors as a target for cognition-enhancing drugs. The dual binding and functional selectivity offers an ideal profile for cognition-enhancing effects without the unwanted side effects associated with activity at other GABAA receptor subtypes.
KeywordsGABAA receptors Benzodiazepine Inverse agonist Long-term potentiation Cognition Delayed match to position Morris water maze Object retrieval Monkey Rat
We would like to acknowledge the expert technical assistance of Sebastian Debilly, Michel Enderlin, Patricia Glaentzlin, Jasmin Graehler, Cecile Guizani, Rachel Haab, Marie Haman, Marie-Laurence Harle-Yge, Maria Karg, Yeter Kolb, Roland Mory, Marie Claire Pflimlin, Pascal Pflimlin, Stefanie Saenger, Severine Weil-Bandinelli, Michael Weber, Roger Wyler. We would like to thank Dr. Joachim Manns for formulation support.
- Birks J, Harvey RJ (2006) Donepezil for dementia due to Alzheimer’s disease. Cochrane Database Syst Rev:CD001190Google Scholar
- Bonin RP, Martin LJ, Macdonald JF, Orser BA (2007) α5 GABAA receptors regulate the intrinsic excitability of mouse hippocampal pyramidal neurons. J NeurophysiolGoogle Scholar
- Collinson N, Kuenzi FM, Jarolimek W, Maubach KA, Cothliff R, Sur C, Smith A, Otu FM, Howell O, Atack JR, McKernan RM, Seabrook GR, Dawson GR, Whiting PJ, Rosahl TW (2002) Enhanced learning and memory and altered GABAergic synaptic transmission in mice lacking the α5 subunit of the GABAA receptor. J Neurosci 22:5572–5580PubMedGoogle Scholar
- Dawson GR, Maubach KA, Collinson N, Cobain M, Everitt BJ, MacLeod AM, Choudhury HI, McDonald LM, Pillai G, Rycroft W, Smith AJ, Sternfeld F, Tattersall FD, Wafford KA, Reynolds DS, Seabrook GR, Atack JR (2006) An inverse agonist selective for α5 subunit-containing GABAA receptors enhances cognition. J Pharmacol Exp Ther 316:1335–1345PubMedCrossRefGoogle Scholar
- Hadingham KL, Wingrove P, Le Bourdelles B, Palmer KJ, Ragan CI, Whiting PJ (1993) Cloning of cDNA sequences encoding human α2 and α3 GABAA receptor subunits and characterization of the benzodiazepine pharmacology of recombinant α1-, α2-, α3-, and α5-containing human GABAA receptors. Mol Pharmacol 43:970–975PubMedGoogle Scholar
- Lingford-Hughes A, Hume SP, Feeney A, Hirani E, Osman S, Cunningham VJ, Pike VW, Brooks DJ, Nutt DJ (2002) Imaging the GABA-benzodiazepine receptor subtype containing the α5-subunit in vivo with [11C]Ro15 4513 positron emission tomography. J Cereb Blood Flow Metab 22:878–889PubMedCrossRefGoogle Scholar
- McKernan RM, Rosahl TW, Reynolds DS, Sur C, Wafford KA, Atack JR, Farrar S, Myers J, Cook G, Ferris P, Garrett L, Bristow L, Marshall G, Macaulay A, Brown N, Howell O, Moore KW, Carling RW, Street LJ, Castro JL, Ragan CI, Dawson GR, Whiting PJ (2000) Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABAA receptor α1 subtype. Nat Neurosci 3:587–592PubMedCrossRefGoogle Scholar
- McNamara RK, Skelton RW (1993) Benzodiazepine receptor antagonists flumazenil and CGS 8216 and inverse- agonist beta-CCM enhance spatial learning in the rat: dissociation from anxiogenic actions. Psychobiology 21:101–108Google Scholar
- McShane R, Areosa Sastre A, Minakaran N (2006) Memantine for dementia. Cochrane Database Syst Rev:CD003154Google Scholar
- Savic MM, Clayton T, Furtmuller R, Gavrilovic I, Samardzic J, Savic S, Huck S, Sieghart W, Cook JM (2008) PWZ-029, a compound with moderate inverse agonist functional selectivity at GABAA receptors containing α5 subunits, improves passive, but not active, avoidance learning in rats. Brain Res 1208:150–159PubMedCrossRefGoogle Scholar
- Sternfeld F, Carling RW, Jelley RA, Ladduwahetty T, Merchant KJ, Moore KW, Reeve AJ, Street LJ, O’Connor D, Sohal B, Atack JR, Cook S, Seabrook G, Wafford K, Tattersall FD, Collinson N, Dawson GR, Castro JL, MacLeod AM (2004) Selective, orally active GABAA α5 receptor inverse agonists as cognition enhancers. J Med Chem 47:2176–2179PubMedCrossRefGoogle Scholar
- Wilkinson LS, Dias R, Thomas KL, Augood SJ, Everitt BJ, Robbins TW, Roberts AC (1997) Contrasting effects of excitotoxic lesions of the prefrontal cortex on the behavioural response to D-amphetamine and presynaptic and postsynaptic measures of striatal dopamine function in monkeys. Neuroscience 80:717–730PubMedCrossRefGoogle Scholar